Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center
about
New strategies in chronic lymphocytic leukemia: shifting treatment paradigmsThe shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 studyRole of allogeneic transplantation in patients with chronic lymphocytic leukemia in the era of novel therapies: a reviewManaging high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cellsThree-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.Vincristine activates c-Jun N-terminal kinase in chronic lymphocytic leukaemia in vivoA new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53.How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?Where does allogeneic stem cell transplantation fit in the treatment of chronic lymphocytic leukemia?Patients with relapsed/refractory chronic lymphocytic leukaemia may benefit from inclusion in clinical trials irrespective of the therapy received: a case-control retrospective analsysis.Efficacy and Safety of Ibrutinib in Indian Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: Cases from a Named Patient Program.
P2860
Q26828496-72FB48F7-C789-4A59-9C28-F176F2E78F72Q30243968-D8E7F01B-FA8E-4F34-80C7-CBB7A2607FE2Q34240404-2B3E08BE-8B0D-47BC-B9C2-3851D3E56C13Q34348572-26B834F3-22DC-41A3-BB40-9F91DA053AD9Q34769213-2F4C80A1-8185-4AF5-A1A3-98A1D2AE6527Q34876742-57BB1FBF-2290-4757-936D-0B8A7F83B373Q35450520-3B5EC293-1D81-436A-A26C-3D52D6CCBBD3Q36072490-7F8003C7-B069-45DD-AE1C-B1A49CC23D49Q38231432-DDC39C65-6B6E-4613-88AA-554CAE2473EFQ38340201-0583D62A-17C7-486F-BAE0-CFFAC2746D00Q38344296-2D43CD70-A489-4406-89D5-5230E851B7ABQ43185843-A48A040A-B60F-4BBC-92DD-E80E4FF50AE2Q49731233-F8B83AE5-CA9E-4EAC-A223-CF1711C46A8A
P2860
Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Impact of targeted therapy on ...... ) karyotype at a single center
@ast
Impact of targeted therapy on ...... ) karyotype at a single center
@en
type
label
Impact of targeted therapy on ...... ) karyotype at a single center
@ast
Impact of targeted therapy on ...... ) karyotype at a single center
@en
prefLabel
Impact of targeted therapy on ...... ) karyotype at a single center
@ast
Impact of targeted therapy on ...... ) karyotype at a single center
@en
P2093
P2860
P921
P356
P1433
P1476
Impact of targeted therapy on ...... ) karyotype at a single center
@en
P2093
A J Johnson
A S Ruppert
G Lozanski
K Maddocks
L A Andritsos
M R Grever
P2860
P2888
P304
P356
10.1038/LEU.2014.42
P577
2014-01-23T00:00:00Z
P5875
P6179
1025936542